Quarterly report pursuant to Section 13 or 15(d)

Basis of Presentation and Summary of Significant Accounting Policies (Details Narrative)

v3.19.2
Basis of Presentation and Summary of Significant Accounting Policies (Details Narrative) - USD ($)
1 Months Ended 3 Months Ended 6 Months Ended
Jul. 31, 2019
Jun. 30, 2019
Jun. 30, 2018
Jun. 30, 2019
Jun. 30, 2018
Jan. 02, 2019
Dec. 31, 2018
Net Loss   $ 5,297,271 $ 362,722 $ 8,992,087 $ 1,259,922    
Bad debt expenses     60,000        
Current lease liabilities   482,632   482,632    
Long-term lease liabilities   511,930   511,930    
ROU assets   973,386   973,386    
Other receivables   65,865   65,865     5,144
Deferred revenue recognition   838,377   838,377     $ 326,064
Advertising costs   1,584,850 $ 419,337 $ 2,720,396 $ 1,156,842    
Anti-dilutive securities            
Warrants [Member]              
Anti-dilutive securities       30,108,743      
Common Stock Options [Member]              
Anti-dilutive securities       517,509      
Lung Institute, LLC [Member]              
Other receivables   53,000   $ 53,000      
Reimbursement receivable   9,000   9,000      
Regenerative Medicine Solutions, LLC [Member]              
Reimbursement receivable   $ 4,000   $ 4,000      
Lung Institute Tampa, LLC [Member] | Subsequent Event [Member]              
Repayments to related party $ 20,000            
Accounting Standards Update (ASU) No. 2016-02 [Member]              
Current lease liabilities           $ 475,000  
Long-term lease liabilities           713,000  
ROU assets           $ 1,167,000